within Pharmacolibrary.Drugs.ATC.B;

model B01AF51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AF51</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Combination of rivaroxaban, a direct oral factor Xa inhibitor anticoagulant, and acetylsalicylic acid (aspirin), an antiplatelet agent used to reduce blood clot formation. This drug combination is approved in some countries for prevention of atherothrombotic events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for the fixed-dose combination in healthy adults, based on individual PK profiles of rivaroxaban and acetylsalicylic acid. No direct clinical publication reporting validated population PK parameters for the combination under ATC B01AF51 found.</p><h4>References</h4><ol><li><p>Abrignani, MG, et al., &amp; Monica, F (2021). Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). <i>European journal of internal medicine</i> 85 1–13. DOI:<a href=\"https://doi.org/10.1016/j.ejim.2020.11.014\">10.1016/j.ejim.2020.11.014</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33279389/\">https://pubmed.ncbi.nlm.nih.gov/33279389</a></p></li><li><p>Kakar, P, et al., &amp; Lip, GY (2007). Rivaroxaban. <i>Drugs of today (Barcelona, Spain : 1998)</i> 43(3) 129–136. DOI:<a href=\"https://doi.org/10.1358/dot.2007.43.3.1067345\">10.1358/dot.2007.43.3.1067345</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17380210/\">https://pubmed.ncbi.nlm.nih.gov/17380210</a></p></li><li><p>Kubitza, D, et al., &amp; Zuehlsdorf, M (2006). Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. <i>Journal of clinical pharmacology</i> 46(9) 981–990. DOI:<a href=\"https://doi.org/10.1177/0091270006292127\">10.1177/0091270006292127</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16920892/\">https://pubmed.ncbi.nlm.nih.gov/16920892</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AF51;
